288 results about "Quinoxaline" patented technology

The present invention discloses a series of fluorine-substituted heterocyclic compounds, specifically, compounds represented by formula (XII) and pharmaceutically acceptable salts thereof. 【Chemical 1】 JPEG2025516367000403.jpg44170

The invention discloses a hole transport material, a preparation method thereof and a perovskite solar cell, and belongs to the technical field of photovoltaic solar materials. The molecular structural formula of the compound is shown as a formula (I) or a formula (II). According to the invention, a quinoxaline part is used as an electron acceptor for extended conjugate modification, a plurality of single donors such as triphenylamine electron donating groups, dihydroacenaphthene, binaphthyloxy and the like are introduced, the hole transport material with a multi-donor structure is constructed, and the hole transport material adjusts the distribution of HOMO-LUMO, increases charge transfer channels, improves the separation and transport capabilities of charges, and improves the hole transport efficiency. Therefore, the mobility of current carriers is improved. A tert-butyl unit is further introduced to the periphery of the triphenylamine group, the hydrophobic property of tert-butyl reduces the interface energy barrier between the hole transport layer and the perovskite precursor solution, directional growth and defect passivation of perovskite crystals are promoted, and the crystallization quality of the perovskite thin film and the device performance are improved.

The invention discloses a star-shaped tripolymer type non-fullerene acceptor material as well as preparation and application thereof. The star-shaped tripolymer type non-fullerene acceptor material has a structure as shown in the following formula: # imgabs0 #. According to the invention, a star-shaped trimer type oligomer material connected with a quinoxaline development center with a derivative site in the middle is adopted, so that the defect that the PCE of the current oligomer type acceptor material is influenced due to oligomerization based on a halogen substitution site of tail-end isatin is overcome; compared with a traditional small molecule material (oligomer type acceptor material), the material has higher open-circuit voltage (Voc), the photoelectric conversion efficiency is excellent, the illumination stability is good, and when the material is applied to a solar cell, the photoelectric conversion efficiency and stability of the cell can be remarkably improved.

The invention provides a preparation method of a brominated benzhydryl quinoxaline ketone compound, which comprises the following step: under the condition of illumination, carrying out coupling reaction on 1-methylquinoxaline ketone and brominated diphenylmethane to obtain the brominated benzhydryl quinoxaline ketone compound. The preparation method of the brominated benzhydryl quinoxaline ketone compound provided by the invention is mild in reaction condition and simple and efficient in step.

The invention relates to 3-quinoxalinyl imidazoline thioketone derivatives, a synthesis method and application technical contents. The structural general formula of the derivative is formula 1 or formula 2. The invention provides a preparation method of the derivative. The invention proves that the developed 3-quinoxalinyl imidazoline thioketone derivative has an anti-myocardial hypertrophy effect and can be applied to preparation, research and development of anti-myocardial hypertrophy drugs.

An organometallic complex having an emission peak in a long wavelength region (a visible region having a wavelength of 700 nm or greater or a near-infrared region) is provided. The organometallic complex has a structure represented by General Formula (G1), in which a ligand having a quinoxaline skeleton is coordinated to a central metal, and an electron-withdrawing group (e.g., fluorine, a cyano group, a trifluoromethyl group, a trifluoromethylsulfonyl group, or a pentafluorosulfanyl group) is included as a substituent at at least one substitutable position of the benzene ring of the quinoxaline skeleton of the ligand.

The present invention provides a fluorine-containing electrochromic polymer, a preparation method thereof and an application thereof. The fluorine-containing electrochromic polymer has a structure shown in Formula I. In the present invention, by introducing fluorine atoms into the electrochromic polymer and through the interaction between the fluorine atoms and a single alkoxy group with a specific structure on the quinoxaline group, the prepared fluorine-containing electrochromic polymer has excellent properties, and thus the prepared electrochromic device has a lower starting voltage, a lower contrast attenuation rate, a faster response speed and a higher coloring efficiency.

The application belongs to the field of compound synthesis and particularly relates to a photocatalytic preparation method of quinoxaline-2,3-dione compounds, which comprises the following steps: preparing a raw material solution containing quinoxaline-2-ketone, mercaptan, a photocatalyst and acetonitrile, and performing a photocatalytic reaction under light to obtain a quinoxaline-2,3-dione compound product; the mercaptan is C1-C4 alkyl mercaptan, and the -SH is connected to a primary carbon or a secondary carbon. The application adopts a photocatalytic method to perform hydroxylation on the C3 position of quinoxaline-2-ketone, and further controls the combination of the mercaptan and acetonitrile solvent to improve the photocatalytic reaction effect of C3 hydroxylation.

The present invention discloses an efficient C-H arylation reaction between quinoxalinone compounds and aryltriazenes induced by ionic liquids. Specifically, it relates to a method for the electrochemical synthesis of 3-arylquinoxalinone compounds, using aryltriazenes as stable arylation reagents and ionic liquids as promoters and electrolytes. Under mild, metal-free, and oxidant-free conditions, the method can synthesize a variety of 3-arylquinoxalinone compounds and arylated quinoxaline compounds in moderate to excellent yields. This scheme has the remarkable characteristics of simple operation, excellent functional group tolerance, high selectivity, strong product derivatization, and suitability for gram-scale continuous flow chemical synthesis.

The disclosure relates to analogs of quinoxaline / quinoline cytotoxic agents, termed"Nupomycins" herein, linker-payloads, and protein-drug conjugates thereof, pharmaceutical compositions comprising same, and methods of treating disease therewith.

The application discloses a preparation method of a diphenylmethyl quinoxaline ketone derivative, and belongs to the technical field of biological medicines. The structure of the diphenylmethyl quinoxaline ketone derivative is shown in the specification. The application adopts a cross dehydrogenative coupling strategy, realizes quinoxaline ketone 3-alkylation through direct activation of an alkane and accompanying hydrogen atom transfer, and has the advantages of mild reaction conditions, cheap and easily available reagents, and higher efficiency and environmental friendliness. The diphenylmethyl quinoxaline ketone derivative has high-efficiency and broad-spectrum antifungal activity, shows inhibitory effects on a plurality of common plant pathogenic fungi, and can be developed into a product for treating plant fungal infections.

The invention belongs to the technical field of organic solar cell materials, and relates to a benzodithiophene polymer donor with a simple and stable structure and a preparation method and application thereof. The invention discloses a benzodithiophene polymer donor PBTQ-X (F / Cl / 2F) with a simple and stable structure, and discloses a preparation method of the benzodithiophene polymer donor PBTQ-X (F / Cl / 2F), and the preparation method comprises the following steps: under the action of a Stille coupling catalyst, carrying out two-stage polymerization on benzodithiophene containing bis (trimethyltin) and a quinoxaline derivative containing a dibromothiophene pi bridge, carrying out two-stage heating reflux reaction, and carrying out post-treatment to obtain the benzodithiophene polymer donor PBTQ-X (F / Cl / 2F). Adding an end-capping reagent for end capping; and finally, settling after passing through methanol, thereby obtaining the product. The benzodithiophene polymer donor with a simple and stable structure can be applied to an active layer of an organic solar cell device, and shows relatively good photovoltaic performance and long-term stability.

The present invention relates to a nitrogen-containing fused ring compound and its application in an organic electroluminescent device. The structure of the nitrogen-containing fused ring compound is shown in Formula I. In Formula I, X and Y are the same or different and are each independently oxygen or sulfur; Z is oxygen, sulfur or N-R, where R is an alkyl group or an aryl group; R 1 、R 2 、R 3 and R 4 are the same or different and are each independently H, an alkyl group, an aryl group or a heteroaryl group, and R 1 、R 2 、R 3 and R 4 one or more of them are heteroaryl groups having a nitrogen heterocycle, and the nitrogen-containing heterocycle is selected from one or more of a pyrimidine ring, a quinoxaline ring, a quinazoline ring and a triazine ring. When L 3 and L 4 do not exist, R 3 and R 4 are not H; L 1 、L 2 、L 3 and L 4 are the same or different and are each independently selected from non-existence, arylene and heteroarylene. When the compound of the present invention is applied to an organic electroluminescent device, it has a lower driving voltage and a higher device luminous efficiency.

This invention discloses a polysubstituted indole[1,2-a]quinoxaline compound, its preparation method, and its applications. The structural formula of the polysubstituted indole[1,2-a]quinoxaline compound of this invention is or , where R 1 Selected from -H or -F, R 2 The compounds are selected from phenyl, 4-methylphenyl, 4-methoxyphenyl, or 4-fluorophenyl. The polysubstituted indole[1,2-a]quinoxaline compounds of this invention have novel structures and significant antitumor activity, making them suitable for the synthesis of anticancer drugs. Furthermore, their preparation methods offer advantages such as readily available and inexpensive catalysts, broad substrate applicability, good functional group tolerance, simple operation, mild reaction conditions, and high step economy, making them suitable for large-scale industrial production and application.

The present invention relates to novel heteroaryl-substituted (aza)quinoxaline derivatives of the general formula (I), in which the structural elements A1, A2, A3, A4, R1, R2, R3, R4 and R5 have the meaning given in the description, to formulations and compositions comprising such compounds and for their use in the control of animal pests including arthropods and insects in plant protection and to their use for control of ectoparasites on animals.

The invention discloses a near-infrared two-region aggregation-induced emission I-type photosensitizer as well as preparation and application thereof. The chemical structural general formula of the near-infrared two-region aggregation-induced emission I-type photosensitizer is shown in the specification, wherein X is independently selected from one of O, S and Se, R1 is independently selected from one of straight-chain alkyl groups with the carbon atom number of 1-20, R2 is independently selected from one of-F,-CN,-CF3,-OCH3,-C4H9 and-CH3, and R3 is independently selected from one of-H,-Br,-I and-TPA. A D-pi-A-pi-D type near-infrared two-region aggregation-induced emission I type photosensitizer is designed and synthesized, and 4, 4 '-dimethoxydiphenylamine is used as a distortion donor unit, ortho-substituted hexylthiophene is used as a pi-bridge, and acenaphthene alkene thiadiazolo quinoxaline and other derivatives are used as central acceptor units. The near-infrared two-region aggregation-induced emission type I photosensitizer has good fluorescence and active oxygen generation and photothermal conversion capabilities, and can be used for cancer multi-mode diagnosis and treatment integrated research.

A combination for use in treating cancer is provided. The combination comprises a therapeutically effective amount of an inhibitor of nuclear import protein Karyopherin Beta 1 (Kpnβ1) such as the substituted pyrrolo[2,3-b]quinoxalines of Formula I and a therapeutically effective amount of an inhibitor of nuclear export protein Chromosome Maintenance 1 (Crm1) such as the hydrazide- containing compounds of Formula II. The combination therapy provides an enhanced anti-cancer therapeutic effect compared to the effect of each of the nuclear transport inhibitors administered alone.

The application provides an organic negative electrode and a metal-air battery, the organic negative electrode comprises an organic matter with a low redox potential, the organic matter with the low redox potential comprises phenazine, diquinoxaline phenazine, a nitrogen heterocyclic ring, a carboxylate or an azo compound, the organic matter in the organic negative electrode is corrosion resistant and the redox potential can be adjusted, even reaching a negative reduction potential comparable to that of hydrogen, so that the phenomenon of hydrogen evolution corrosion cannot occur; a large number of functional groups and active sites in the organic matter can induce uniform deposition of metal ions, and there is no condition for dendrite growth and formation of a passivation layer, so that various problems caused by the above metal negative electrode can be completely avoided; the metal-air battery with the above organic negative electrode has the advantages of long cycle time, stable performance, safety, environmental protection and low cost, and has a wide application prospect in the field of large-scale energy storage.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a quinoxaline compound as well as a preparation method and application thereof. Specifically, the quinoxaline compound provided by the invention is screened by adopting virtual screening and pharmacophore modes, is novel in structure, has relatively good inhibitory activity on MELK, and solves the problem of insufficient development of an existing MELK inhibitor that the activity is not ideal enough, the chemical structure is not diversified enough and the like.

The invention provides a method for synthesizing a 3-alkylated quinoxaline-2 (1H)-ketone compound through visible light catalysis and application of the 3-alkylated quinoxaline-2 (1H)-ketone compound, and belongs to the technical field of catalytic synthesis. The method comprises the following steps: under visible light, a quinoxaline-2 (1H)-ketone derivative is excited by light to reach an excited state and then reacts with an alkylating reagent to obtain an alkyl carbon free radical; further, the quinoxaline-2 (1H)-ketone is attacked, so that the synthesis of the 3-alkylated quinoxaline-2 (1H)-ketone derivative is realized; according to the method, the quinoxaline-2 (1H)-ketone derivative is directly excited under the visible light condition, no extra photocatalyst is needed, the application of an equivalent oxidant is avoided due to the use of a catalytic amount of cobalt catalyst, and particularly, the method also has the advantages of simple reaction raw materials, high product yield and mild reaction conditions.

The application discloses a kind of all-organic aqueous zinc ion battery positive electrode materials and preparation method and application, belong to new energy materials and battery technical field, and positive electrode material is nitrogen heterocyclic organic 5,5,12,12'-tetrahydro-2,2'-bi quinoxaline [2,3-b] quinoxaline, negative electrode material is imine and carbonyl organic matter.Nitrogen heterocyclic organic positive electrode loses electron and is oxidized in charging process, and imine and carbonyl organic negative electrode obtains electron and is reduced, so stable charge-discharge cycle can be carried out.The application uses the above-mentioned one all-organic aqueous zinc ion battery positive electrode material and preparation method and application, using structure adjustable and element rich organic positive electrode, relatively stable imine and carbonyl organic negative electrode, environment-friendly and safe water-based electrolyte, can realize the stable charge-discharge of all-organic aqueous zinc ion battery.

The invention relates to the technical field of proton batteries, and discloses a holosymmetric organic sub-battery and a preparation method thereof. The holosymmetric organic sub-battery comprises a positive electrode, a negative electrode, a diaphragm and an electrolyte, the positive electrode is an organic electrode which is subjected to complete discharge treatment, and the negative electrode is an organic electrode which is not subjected to discharge treatment; the organic electrode comprises a current collector and an active material, wherein the active material is a vinyl covalent organic framework material; the electrolyte is an aqueous solution of zinc salt. 2, 3, 7, 8-tetramethylpyrazino [2, 3-g] quinoxaline and a symmetric monomer containing an aldehyde group are subjected to polycondensation and purification through melt polymerization to obtain the vinyl covalent organic framework material, and the vinyl covalent organic framework material has a unique two-step proton redox behavior. The material is used as an active substance for the holosymmetric organic sub-battery, and the specific capacity and the cycle performance of the holosymmetric organic sub-battery are improved by utilizing the unique two-step proton embedding and removing behaviors of the material.

This invention provides a method for preparing 4,1-disubstituted pyrrolo[1,2-a]quinoxaline-1-yl ketone derivatives, belonging to the field of organic synthesis technology. This invention uses 2-(1H-pyrrolo-1-yl)aniline compounds and α-carbonyl acids as reactants, employing only ammonium persulfate as an oxidant. Under metal-free catalysis, a one-pot tandem reaction is carried out to simultaneously complete the cyclization of the pyrrolo[1,2-a]quinoxaline nucleus and the C-1 acylation modification. The substituents at the 4- and 1-positions of the product can be flexibly controlled by changing the α-carbonyl acid with different structures. This method requires no pre-modified substrate, eliminates the need for metal catalysts, avoids the risk of metal residue, and features simplified steps and high functional group compatibility, providing a new green and low-cost route for the synthesis of polysubstituted pyrrolo[1,2-a]quinoxaline ketone derivatives.

The present disclosure relates to Lumateperone intermediates and a process for their preparation. Particularly, the present disclosure relates to ethyl (6bR,10aS)-3-methyl- 2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de] quinoxaline-8(7H)- carboxylate salts and a process for their preparation and a process for preparation of lumateperone intermediate thereof. The process of the present disclosure is simple, cost- effective, commercially scalable and environment friendly. The process of the present disclosure proceeds under mild reaction conditions thereby reducing the formation of impurities.

The invention provides an application of Akti-1 / 2 in preparation of an anti-new coronavirus drug. And the new coronavirus is SARS-CoV-2 (Sarcabose Region The chemical name of the Akti-1 / 2 is 1, 3-dihydro-1-[1-[4-(6-phenyl-1H-imidazo [4, 5-g] quinoxaline-7-yl) phenylmethyl]-4-piperidinyl]-2H-benzimidazole-2-ketone, in-vitro Vero cell infection model research shows that the Akti-1 / 2 can inhibit replication of an original strain of the new coronavirus (SARS-CoV-2), and the activity of resisting the new coronavirus is achieved. In a Vero cell infection model, the IC50 (half maximal inhibitory concentration) of the SARS-CoV-2 original strain is 0.039 [mu] M. Therefore, the Akti-1 / 2 can be used for research and development of anti-new coronavirus infection drugs, and has a good development prospect.

The invention discloses a biopolymer, and particularly relates to a carbazolyl conjugated polymer, in particular to a carbazole-quinoxaline biopolymer formed by polymerizing a carbazole monomer and a quinoxaline monomer, and an electric storage device with three resistivity states is manufactured by taking the biopolymer as an organic layer. The electric storage device is high in switching current ratio and low in starting voltage, and has good performance of quick response and multiple cyclic read-write. The binary copolymer is excellent in performance, simple in synthesis method, simple and convenient in memory device manufacturing process, excellent in ternary memory performance, low in cost and capable of realizing industrial production, and has a good application prospect in the field of information storage.

The application discloses a synthesis method of C3-substituted quinoxaline ketone derivatives and application thereof. A series of C3-substituted quinoxaline ketone derivatives with both terpene and quinoxaline ketone biological activity skeletons are obtained by using N-alkoxy phthalimide and quinoxaline ketone as starting substrates, under the catalysis of a photocatalyst and visible light irradiation, and at a temperature of 55-65 DEG C for 10-15 h. The application has the advantages of stable and easy-to-prepare raw materials, mild reaction conditions, simple experimental operation, good chemical selectivity and functional group tolerance, and is a green chemical synthesis method with good application prospect. The activity experiment results show that the synthesized C3-substituted quinoxaline ketone derivatives have good inhibiting effect on the growth of plant pathogenic fungi.

The present invention addresses the problem of providing a light-emitting element having excellent luminous efficiency and a highly durable lifespan.　This compound is represented by general formula (1). (In general formula (1), L is a substituted or unsubstituted arylene group or a substituted or unsubstituted heteroarylene group. However, when these groups are substituted, the substituent groups are alkyl groups or alkoxy groups. n is an integer of 2-5. In addition, at least one of the n Ls has a structure represented by general formula (2). A is a substituted or unsubstituted pyrimidyl group, a substituted or unsubstituted triazinyl group, a substituted or unsubstituted quinoxalinyl group, or a substituted or unsubstituted quinazolinyl group. However, when these groups have substituents, the substituents do not form a ring structure. B is a hydrogen atom, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group.) (In general formula (2), R1-R4 are each independently a hydrogen atom, an alkyl or an alkoxy group, and R1-R4 do not bond to each other to form a ring. * represents a bonding position with an adjacent substituent.)

The invention relates to quinoxaline derivatives as anti-cancer drugs. Specifically, the invention relates to azaquinolone compounds of formula (I) and their use in medicine.